Lucentis improves anatomic outcomes

Article

Ranibizumab (Lucentis) helps improve anatomic outcomes in patients with neovascular age-related macular degeneration (AMD), according to Nancy HoleKamp, MD speaking at the retina free paper session at the 2006 AAO meeting in Las Vegas.

Ranibizumab (Lucentis) helps improve anatomic outcomes in patients with neovascular age-related macular degeneration (AMD), according to Nancy HoleKamp, MD speaking at the retina free paper session at the 2006 AAO meeting in Las Vegas.

In a retrospective analysis of the Phase III MARINA study results, patients with neovascular AMD who were treated with a 0.5 mg dose of ranibizumab demonstrated improvement in anatomic outcomes that corresponded to improved visual acuity (VA).

Fluorescein angiography (FA) and optical coherence tomography (OCT) were used to assess anatomic changes for patients receiving ranibizumab or sham injection over 24 months for FA and 12 months for OCT, explained Dr Holekamp. The key anatomic endpoints were: mean total lesion area at 24 months; total area of CNV at 24 months; mean area of leakage at 24 months; mean foveal retinal thickness at 12 months.

Ranibizumab was shown to have favourable anatomic outcomes with little growth in the mean total lesion area, no growth of CNV, decreased leakage, and significant thinning of the retina, Dr Holekamp said.

"These anatomic changes were consistent with visual outcomes," she concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.